Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 12:59 pm Sale | 2025-09-30 | 13G | Erasca, Inc. ERAS | Logos Global Management LP | 13,600,000 4.800% | -1,500,000 (-9.93%) | Filing History |
| 2025-08-14 4:56 pm Purchase | 2025-06-30 | 13G | Erasca, Inc. ERAS | Logos Global Management LP | 15,100,000 5.300% | 15,100,000 (New Position) | Filing History |
| 2025-08-14 1:10 pm Sale | 2025-06-30 | 13G | Erasca, Inc. ERAS | Frazier Life Sciences Public Fund, L.P. | 15,038,753 5.300% | -7,537,098 (-33.39%) | Filing History |
| 2025-08-14 12:12 pm Purchase | 2025-06-30 | 13G | Erasca, Inc. ERAS | T. Rowe Price Investment Management, Inc. | 20,332,161 7.200% | 3,501,305 (+20.80%) | Filing History |
| 2025-08-13 8:14 pm Purchase | 2025-06-30 | 13G | Erasca, Inc. ERAS | SUVRETTA CAPITAL MANAGEMENT, LLC | 14,502,004 5.100% | 2,187,000 (+17.76%) | Filing History |
| 2025-05-15 09:44 am Purchase | 2025-03-31 | 13G | Erasca, Inc. ERAS | Frazier Life Sciences Public Fund, L.P. | 22,575,851 8.000% | 6,359,635 (+39.22%) | Filing History |
| 2025-02-13 8:09 pm Sale | 2024-12-31 | 13G | Erasca, Inc. ERAS | SUVRETTA CAPITAL MANAGEMENT, LLC | 12,315,004 4.400% | -1,453,035 (-10.55%) | Filing History |
| 2025-02-12 5:02 pm Unchanged | 2024-12-31 | 13G | Erasca, Inc. ERAS | Novartis Pharma AG | 12,307,692 4.400% | 0 (Unchanged) | Filing History |
| 2024-11-14 5:13 pm Sale | 2024-05-21 | 13G | Erasca, Inc. ERAS | ARCH Venture Fund X L.P. | 0 0.000% | -11,055,554 (Position Closed) | Filing History |
| 2024-11-14 4:04 pm Sale | 2024-09-30 | 13G | Erasca, Inc. ERAS | Armistice Capital, LLC | 0 0.000% | -8,096,000 (Position Closed) | Filing History |
| 2024-11-14 1:28 pm Purchase | 2024-09-30 | 13G | Erasca, Inc. ERAS | T. Rowe Price Investment Management, Inc. | 16,830,856 6.000% | 16,830,856 (New Position) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Erasca, Inc. ERAS | BlackRock Inc. BLK | 15,358,280 5.400% | 0 (Unchanged) | Filing History |
| 2024-10-29 8:28 pm Purchase | 2024-09-30 | 13G | Erasca, Inc. ERAS | City Hill LLC | 33,902,800 11.900% | 776,724 (+2.34%) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Erasca, Inc. ERAS | BlackRock Inc. BLK | 15,358,280 5.400% | 15,358,280 (New Position) | Filing History |
| 2024-05-31 4:18 pm Purchase | 2024-05-21 | 13G | Erasca, Inc. ERAS | Venrock Healthcare Capital Partners III, L.P. | 16,216,216 6.500% | 16,216,216 (New Position) | Filing History |
| 2024-05-29 11:55 am Purchase | 2024-05-21 | 13G | Erasca, Inc. ERAS | Frazier Life Sciences Public Fund, L.P. | 16,216,216 5.900% | 16,216,216 (New Position) | Filing History |
| 2024-05-28 4:34 pm Purchase | 2024-05-17 | 13G | Erasca, Inc. ERAS | SUVRETTA CAPITAL MANAGEMENT, LLC | 13,768,039 5.500% | 13,768,039 (New Position) | Filing History |
| 2024-02-14 3:36 pm Purchase | 2023-12-31 | 13G | Erasca, Inc. ERAS | Armistice Capital, LLC | 8,096,000 5.360% | 8,096,000 (New Position) | Filing History |
| 2024-02-13 8:24 pm Purchase | 2023-12-31 | 13G | Erasca, Inc. ERAS | City Hill LLC | 33,126,076 21.800% | 2,832,750 (+9.35%) | Filing History |
| 2024-01-30 4:41 pm Sale | 2023-11-29 | 13D | Erasca, Inc. ERAS | Cormorant Asset Management, LP | 0 0.000% | -10,893,107 (Position Closed) | Filing History |